Loop Biz – Lifestyle
Author:
Monte Rosa Therapeutics, Inc.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
April 20, 2026
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 17, 2026
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
March 16, 2026